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Although it has been more than 100 years since the fITst attempt to produce a 
cholera vaccine was made, an effective cholera vaccine has yet to be developed. In this 
study, the level of protection produced by a potential DNA vaccine (PVax/ctxB) was 
tested against the ctxB toxin of Vibrio cholerae on Balb/c mice. First, the intramuscular 
vaccination method was validated using pCMV plasmid that encodes HbsAg, which was 
detected 5 days after the injection into the tibial muscle. Next, 4 groups of mice were 
intramuscularly injected with either the pVax/ctxB vaccine construct or pVaxl as the 
negative control. The first and second groups received 2 injections spaced 3 weeks apart, 
while the other two groups were given 3 injections spaced 3 weeks apart. This was then 
followed by challenging the mice with 105 or 107 cfulmllmouse from clinical isolates of 
V. cholerae after 3 weeks of the last injection. Antibody levels for both IgG and serum 
IgA were monitored using ELISA, and showed high production of IgG after the first 
booster injection with no significant change of IgA levels. However, after the second 
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booster injection, the antibody levels for both IgG and IgA declined. This was 
accompanied by the death of 2 mice in the first vaccinated group, and all the mice in the 
control group after the bacterial challenge with 107 cfulml/mouse. In the second group, 
none of the mice survived in both vaccinated and control groups. The bacterial challenge 
using 105 cfulmllmouse failed to induce the death in all the groups. 
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Walaupun setelah lebih dari pada 100 tahun semenjak percubaan pertama 
menghasilkan vaksin taun dilakukan, namun sehingga kini penghasilan vaksin yang 
benar-benar efektif masih belum menampakkan hasil. Bagi kajian ini pula, tahap 
ketahanan yang dihasilkan oleh calon vaksin DNA (p V ax/ctxB) telah diuji menentang 
toksin ctxB dari Vibrio cholerae dengan tikus Balb/c sebagai hos. Buat permulaan, 
teknik vaksinasi intramuscular telah di sahkan dengan menggunakan plasmid pCMV 
yang mengkodkan HbsAg yang mana telah dikesan setelah disuntik ke otot tibial 5 hari 
kemudian. Empat kumpulan tikus telah disuntik menggunakan teknik di atas samada 
dengan vaksin p VaxlctxB atau p V ax sebagai kawalan negatif. Kumpulan pertama dan 
kedua menerima 2 suntikan setiap 3 minggu manakala 2 kumpulan lagi 3 suntikan bagi 
setiap 3 minggu. Langkah berikutnya, setiap kumpulan ditentang dengan 105 atau 107 cfu 
yang telah dipencilkan secara klinikal dari V. cholera. Paras antibodi bagi kedua-dua IgG 
dan serum IgA dipantau menggunakan ELISA. Keputusan ELISA menunjukkan paras 
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antibodi IgG tinggi sementara tiada perubahan ketara penghasilan paras 19A setelah 
suntikan booster pertama. Setelah suntikan booster kedua, paras antibodi IgG dan IgA 
didapati menurun. Keadaan ini diikuti dengan kematian 2 ekor tikus dari kumpulan 
pertam<. yang divaksin dan kematian kesemua tikus kumpulan kawalan setelah ditentang 
dengan 107 cfu V cholerae yang virulen. Bagi kumpulan kedua, kesemua tikus (vaksin 
dan kawalan) mati. Tentangan bakteria 105 gagal untuk menyebabkan kematian bagi 
kesemua kumpulan. 
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CHAPTER 1 
INTRODUCTION 
Around 200 years ago, immunization against infectious diseases was started 
when Edward Jenner published his method of preventing smallpox in 1 798 (l). 
Although it took nearly 1 00 years before the appearance of the next vaccine in 1 880, 
vaccine development was rapid, where in 1 884, the first attempt to produce a 
parenteral cholera vaccine of broth cultures of Vibrio cholerae was reported by 
Ferran (2). However, after more than 1 00 years of this first vaccination attempt, no 
effective cholera vaccine is yet available to date. 
The cholera disease can spread easily by water and food contamination, 
causing severe diarrhea and death among people living with poor sanitary facilities. 
Wars and political unrest, climate changes and natural catastrophes, increase the 
number of people under the threat of cholera epidemics. Furthermore, these 
conditions are still prevailing in many parts of the world. On the other hand. the 
increasing number of geographical areas becoming endemic for cholera reflects a 
failure of implementation of control measures. Water and electrolytes replacement 
therapy is not fast enough during times of outbreak, and misguided use of antibiotics 
has led to the emergence of multi-resistant strains, some of which were found to be 
highly virulent (3). 
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As of September 2002, 1 06,547 cases with 3, 1 55 deaths were officially 
reported to the World Health Organization (WHO) (4). In the year 200 1 ,  Malaysia 
reported 557 cases with II deaths. From a total of 1 84,3 1 1  cases 2,728 deaths were 
reported from the whole world (5). 
The need for an effective cholera vaccine is urgent to produce high level of 
protection in people l iving in high-risk areas. A parenteral vaccine based on 
inactivated V. cholerae 0 1  has been available for more than 40 years. Nevertheless, 
this vaccine is not recommended any more by WHO, since its protective efficacy is 
modest, of short duration and it does not prevent the transmission of V. cholerae (3). 
At present, new cholera vaccines are under development, and 2 oral vaccines 
are already available internationally, WC/rBS and CVD 1 03-HgR, which conferred 
good protection in adults. But thus far, all the vaccines being used give only 50% 
protection after 6 months of immunization together with no sustained protection in 
chi ldren under 2 years (3). 
In early 1 990's, the ability of inserted genes into plasmid vectors was studied 
to prompt an immune response; surprisingly the immunity el icited was strong enough 
to protect against infectious diseases. The immune response produced by these 
vaccines, which are termed as DNA vaccines (unlike that produced by conventional 
vaccines) can stimulate both humoral and cellular immune responses. The immune 
response produced was found to be long lasting and it might overcome the deficits of 
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the conventional vaccines used nowadays. In addition, new protection against 
diseases like AIDS, malaria, and hepatitis C can be provided. 
The field of DN A vaccines is developing rapidly. Today, many clinical trials 
are conducted to test the efficacy of DN A vaccines against HIV, hepatitis Band 
some tumors such as B-cel l lymphomas. Despite that, any new vaccine should be 
first tested on small animals to detect the immunogenicity of the antigen expressed, 
followed by testing its protective properties against the challenge. In  addition, before 
proceeding to human clinical trials, the vaccine should be tested on h igher animals to 
adjust the dose and the boosting pattern. 
In an attempt to develop a cholera DN A vaccine, the gene encoding for the B 
subunit of the enterotoxin AB was cloned in pVaxl plasmid vector in a previous 
study (6), fol lowed by successful in vitro expression of the antigen using COS-7 cell 
l ine. 
Hence, this study focuses on the next step, in which the abi lity of this 
potential vaccine to be expressed and elicit an immune response in vivo is tested, or 
in other words to test the antigen's immunogenicity.ln vivo tests based on measuring 
the level of antibody production and the protection level against the challenge w ith 
clinical isolates of Vibrio cholera after intramuscular immunization of this potential 
cholera vaccine were conducted using female BALB/c mice. 
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Objectives 
(l) To validate the intramuscular injection technique using pCMV -S plasmid 
that carries HBsAg in Balb/c mice. 
(2) To test the cholera DNA vaccine (pVaxlctxB) intramuscularly by 
measuring the levels of both IgG and 19A produced after each vaccination 
and compare it to a negative control plasmid (pVaxl) without any insert. 
(3) To determine the efficacy of pVaxlctxB in conferring protection or 
immunity against the challenge with either 10 5 or 10 7 cfulml lmouse of 
clinical isolates of Vibrio cholerae. 
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CHAPTER II 
LITERATURE REVIEW 
Cholera 
History 
As early as the time of Hippocrates and Galen, cholera has sporadically 
affected humans all over the world where some records from this time described 
cholera-like symptoms. However, modern knowledge about cholera started in the 
beginning of 1 9th century, where the English physician John Snow in 1 849 indicated 
the importance of water as the carrier of the disease. In 1 883, Robert Koch succeeded 
to isolate Vibrio cholerae from the intestinal discharges of cholera patients. 
Cholera has smoldered in an endemic fashion on the Indian subcontinent for 
centuries, from where the first long-distance spread of the disease to Europe and the 
Americas began in 1 8 1 7  and by the early 20th century, six waves of cholera had 
spread all  over the world. The ih cholera pandemic caused by the El Tor biotype was 
started in 1 96 1  from Indonesia and spread rapidly to Asia, Europe, Africa and finally 
in 1 99 1  to Latin America, which was free of cholera for more than a century. The ih 
pandemic has not receded; on the contrary, cholera has now become endemic in 
many parts of the world (7). Also, since 1 992, V. cholerae 0 1 39, a new and more 
virulent serogroup variant of El Tor biotype has spread to many parts of Asia (3). 
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Disease 
Cholem is an acute gastrointestinal disease where the production of diarrhea 
is the main symptom. The disease can range from mild in most cases with less than 
1 % mortality to a severe life threatening infection termed as cholem gmvis with more 
than 50% mortality (3, 8). The symptoms might appear as sudden with profuse 
watery diarrhea or there can be some premonitory symptoms like anorexia, 
abdominal discomfort and simple diarrhea. 
Initially the stool passed is brown, but soon it assumes a pale gray color with 
an inoffensive, slightly fishy odor. Mucus in the stool imparts its characteristic rice 
water appeamnce. Resultant water and electrolyte loss leads to thirst, muscle cmmps, 
weakness, and sunken eyes. In cholem gmvis, the mte of water loss may reach 1 LIhr 
leading to tachycardia, hypotention and vascular collapse due to dehydmtion (9, 10). 
If untreated severe metabolic acidosis with potassium depletion, anuria, circulatatory 
collapse and cyanosis can occur, leading to death. 
Major altemtions in mental status are uncommon in adults; the patient usually 
remains well oriented but apathetic, while hypoglycemia, coma and convulsions 
might occur in children. After recovery, very small minority of patients « 1 %) 
continue to carry the pathogen in the gallbladder and excrete it with stools; however, 
most patients are free after about 2 weeks (10). 
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Mode of Transmission 
Cholera infection usually begins with the ingestion of contaminated food or 
water. Food can buffer the acidity of the stomach thus decreasing the infecting dose 
of the bacteria as wel l  as providing an ideal culture medium ( I I ). Furthermore, sea 
food can acquire the bacteria from the environmental sources and causes outbreaks 
or sporadic cases specially if it is uncooked or partially cooked ( 1 2). 
Incubation Period and Infectious Dose 
The incubation period can range from a few hours to 5 days, usually 2-3 days 
and it is dependent in part on the inoculum's size ( 1 3), where 1 03 of bacteria in the 
intestine is enough to start the infection. It is estimated that around lOll bacteria are 
required as an infective dose in normal gastric acidity individuals ( 1 4). 
Age and Susceptibility 
In endemic areas, the disease is concentrated more in children aged 2 to 9 and 
in women in their child bearing years ( 1 5-35 years) where there is a decrease in 
immunity and the exposure to the environment is higher. On the other hand, infants 
under 1 year of age are protected because of breast feeding ( 1 5). Individuals with 
blood group 0 are at higher risk for cholera gravis due to EI Tor biotype and 0139 
V ibrio although the mechanism responsible for this difference is not known ( 1 6); 
also, individuals with gastric achlorhydria have a higher risk for getting the d isease. 
